Patents by Inventor Nancy R. Morin

Nancy R. Morin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Spiro-indolines as Y5 receptor antagonists
    Publication number: 20040063942
    Abstract: Compounds of general structural formula I such as that shown in structural formula II 1
    Type: Application
    Filed: July 21, 2003
    Publication date: April 1, 2004
    Applicants: Merck & Co., Inc., Banyu Parmaceutical Co., Ltd.
    Inventors: Ying-Duo Gao, Douglas J. MacNeil, Lihu Yang, Nancy R. Morin, Takehiro Fukami, Akio Kanatani, Takahiro Fukuroda, Yasuyuki Ishii, Masaki Ihara
  • Spiro-indolines as Y5 receptor antagonists
    Patent number: 6638942
    Abstract: Compounds of general structural formula I are selective NPY Y5 receptor antagonists, useful in the treatment of obesity and the complications associated therewith.
    Type: Grant
    Filed: August 26, 2002
    Date of Patent: October 28, 2003
    Assignees: Merck & Co., Inc., Banyu Pharmaceutical Co., Ltd.
    Inventors: Ying-Duo Gao, Douglas J. MacNeil, Lihu Yang, Nancy R. Morin, Takehiro Fukami, Akio Kanatani, Takahiro Fukuroda, Yasuyuki Ishii, Masaki Ihara
  • NPY Y5 receptor antagonists
    Patent number: 6495559
    Abstract: Compounds of general structural formula I such as that shown in structural formula II are selective NPY Y5 receptor antagonists, useful in the treatment of obesity and the complications associated therewith.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: December 17, 2002
    Assignees: Merck & Co., Inc., Banyu Pharmaceutical Co., Ltd.
    Inventors: Ying-Duo Gao, Douglas J. MacNeil, Lihu Yang, Nancy R. Morin, Takehiro Fukami, Akio Kanatani, Takahiro Fukuroda, Yasuyuki Ishii, Masaki Ihara
  • Spiro-indolines as Y5 receptor antagonists
    Publication number: 20020058813
    Abstract: Compounds of general structural formula I such as that shown in structural formula II 1
    Type: Application
    Filed: June 29, 2001
    Publication date: May 16, 2002
    Inventors: Ying-Duo Gao, Douglas J. Macneil, Lihu Yang, Nancy R. Morin, Takehiro Fukami, Akio Kanatani, Takahiro Fukuroda, Yasuyuki Ishii, Masaki Ihara
  • Spiro-indolines as Y5 receptor antagonists
    Patent number: 6313298
    Abstract: Compounds of general structural formula I such as that shown in structural formula II are selective NPY Y5 receptor antagonists, useful in the treatment of obesity and the complications associated therewith.
    Type: Grant
    Filed: September 7, 2000
    Date of Patent: November 6, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Ying-Duo Gao, Lihu Yang, Douglas J. MacNeil, Nancy R. Morin, Takehiro Fukami, Takahiro Fukuroda, Akio Kanatani, Yasuyuki Ishii, Masaki Ihara
  • Spiro-indolines as Y5 receptor antagonists
    Patent number: 6191160
    Abstract: Compounds of the general structural formula I are selective NPY Y5 receptor antagonists. The compounds and compositions of the present invention are useful in the treatment of obesity and complications associated therewith.
    Type: Grant
    Filed: November 8, 1999
    Date of Patent: February 20, 2001
    Assignees: Merck & Co., Inc., Banyu Pharmaceutical Co., Ltd.
    Inventors: Ying-Duo Gao, Douglas J. MacNeil, Lihu Yang, Nancy R. Morin, Takehiro Fukami, Akio Kanatani, Takahiro Fukuroda, Yasuyuki Ishii, Masaki Ihara
  • DNA encoding 1,3 beta-D glucan synthase subunits
    Patent number: 5821353
    Abstract: DNA molecules encoding proteins involved in biosynthesis of 1,3-beta-D glucan are identified, cloned, expressed and used in in vitro assays to screen for antifungal compounds, including compounds that affect cell wall biosynthesis. The invention includes but is not limited to the purified DNA molecules, assays employing the DNA molecules, proteins encoded by the DNA molecules, cells expressing the DNA molecules and altered forms of the molecules.
    Type: Grant
    Filed: August 1, 1996
    Date of Patent: October 13, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Cameron M. Douglas, Gary L. Chrebet, Joseph Clemas, Mohammed El-Sherbeini, Forrest Foor, Jennifer Nielsen Kahn, Rosemarie Kelly, Jean A. Marrinan, Nancy R. Morin, Janet C. Onishi, Stephen Authur Parent, Naasa M. Ramadan, Elizabeth A. Register, Gan-Ju Shei
  • DNA Cloning vector TG1, derivatives, and processes of making
    Patent number: 4460689
    Abstract: Disclosed is the novel bacteriophage TG1, TG1 derivatives, and the corresponding genome or nucleic acid components of such bacteriophages and derivatives of such genome, which are useful as DNA cloning vectors into organisms, such as bacteria, for example, Streptomyces cattleya NRRL 8057; portions of such phage genome are additionally useful as adjuncts in recombinant DNA cloning procedures, for example: (1) to permit the maintenance of cloned DNA in the host, either in an integrated state or as an autonomous element; (2) to serve as promoters for increasing expression of endogenous or foreign genes wherein said promoters are ligated to such genes or otherwise serve as promoters; and (3) to serve as regulatory elements for achieving control over endogenous and foreign gene expression; as cloning vectors, TG1, its deletion mutants, and other derivatives serve for the amplification and transfer of DNA sequences (genes) coding for useful functions, for example, genes necessary for the production of the antibioti
    Type: Grant
    Filed: March 8, 1983
    Date of Patent: July 17, 1984
    Assignee: Merck & Co., Inc.
    Inventors: Forrest Foor, Nancy R. Morin